Imugene Ebitda vs Reconciled Depreciation Analysis
IMU Stock | 0.04 0 2.56% |
Imugene financial indicator trend analysis is infinitely more than just investigating Imugene recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Imugene is a good investment. Please check the relationship between Imugene Ebitda and its Reconciled Depreciation accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imugene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Ebitda vs Reconciled Depreciation
Ebitda vs Reconciled Depreciation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Imugene Ebitda account and Reconciled Depreciation. At this time, the significance of the direction appears to have pay attention.
The correlation between Imugene's Ebitda and Reconciled Depreciation is -0.96. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of Imugene, assuming nothing else is changed. The correlation between historical values of Imugene's Ebitda and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Imugene are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Ebitda i.e., Imugene's Ebitda and Reconciled Depreciation go up and down completely randomly.
Correlation Coefficient | -0.96 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Ebitda
Reconciled Depreciation
Most indicators from Imugene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Imugene current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imugene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Selling General Administrative is likely to gain to about 47.3 M in 2024. Issuance Of Capital Stock is likely to gain to about 57.5 M in 2024
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 203.4K | 190.3K | 3.3M | 3.5M | Net Interest Income | 71.9K | 1.9M | 4.0M | 4.2M |
Imugene fundamental ratios Correlations
Click cells to compare fundamentals
Imugene Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Imugene fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 65.2M | 71.8M | 147.6M | 197.1M | 151.4M | 159.0M | |
Short Long Term Debt Total | 69.3K | 271.0K | 673.4K | 553.5K | 1.5M | 1.6M | |
Other Current Liab | 1.8M | 3.6M | 2.7M | 3.6M | 22.4M | 23.5M | |
Total Current Liabilities | 2.9M | 4.5M | 7.4M | 6.1M | 29.3M | 30.8M | |
Total Stockholder Equity | 59.8M | 65.0M | 138.7M | 189.6M | 118.3M | 124.2M | |
Property Plant And Equipment Net | 155.6K | 466.0K | 862.8K | 683.0K | 1.7M | 1.8M | |
Current Deferred Revenue | 390.6K | 738.3K | 1.3M | 1.6M | 1.9M | 2.0M | |
Net Debt | (30.0M) | (29.2M) | (99.2M) | (152.6M) | (91.6M) | (87.0M) | |
Retained Earnings | (47.3M) | (65.7M) | (103.5M) | (141.4M) | (289.8M) | (275.3M) | |
Accounts Payable | 1.0M | 759.7K | 4.5M | 2.3M | 6.0M | 6.3M | |
Cash | 30.1M | 29.5M | 99.9M | 153.2M | 93.1M | 97.8M | |
Non Current Assets Total | 30.7M | 35.5M | 33.8M | 31.4M | 38.4M | 40.3M | |
Cash And Short Term Investments | 30.1M | 29.5M | 99.9M | 153.2M | 94.5M | 99.3M | |
Net Receivables | 4.2M | 6.7M | 12.8M | 12.1M | 12.6M | 13.2M | |
Common Stock Shares Outstanding | 4.1B | 4.7B | 5.6B | 6.3B | 7.1B | 7.4B | |
Liabilities And Stockholders Equity | 65.2M | 71.8M | 147.6M | 197.1M | 151.4M | 159.0M | |
Non Current Liabilities Total | 2.5M | 2.3M | 1.5M | 1.4M | 3.8M | 4.0M | |
Other Stockholder Equity | (45.5M) | (1.0) | (127.3M) | (173.0M) | (155.7M) | (147.9M) | |
Total Liab | 5.4M | 6.8M | 8.9M | 7.4M | 33.1M | 34.8M | |
Property Plant And Equipment Gross | 155.6K | 718.9K | 1.3M | 1.0M | 2.6M | 2.8M | |
Total Current Assets | 34.5M | 36.3M | 113.8M | 165.7M | 113.0M | 118.7M | |
Accumulated Other Comprehensive Income | 14.3M | 17.6M | 11.4M | 16.7M | 37.8M | 39.7M | |
Short Term Debt | 60.9K | 106.0K | 184.2K | 191.1K | 912.5K | 958.1K | |
Intangible Assets | 30.5M | 34.9M | 32.7M | 30.5M | 34.1M | 35.8M | |
Common Stock | 92.8M | 113.1M | 230.8M | 314.4M | 370.3M | 388.8M | |
Other Liab | 2.5M | 2.2M | 987.1K | 990.6K | 1.1M | 1.1M | |
Net Tangible Assets | 29.3M | 30.1M | 106.0M | 159.1M | 183.0M | 192.2M | |
Long Term Investments | 80.6K | 115.2K | 252.4K | 217.6K | 2.4M | 2.5M | |
Property Plant Equipment | 155.6K | 466.0K | 862.8K | 683.0K | 614.7K | 645.4K | |
Other Current Assets | 194.1K | 170.1K | 1.1M | 401.6K | 5.9M | 6.2M | |
Long Term Debt Total | 8.4K | 165.0K | 489.3K | 362.4K | 326.2K | 462.4K | |
Net Invested Capital | 59.8M | 65.0M | 138.7M | 188.4M | 118.3M | 85.8M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.